Cargando…
Clusterin silencing restores myoblasts viability and down modulates the inflammatory process in osteoporotic disease
BACKGROUND: Targeting new molecular pathways leading to Osteoporosis (OP) and Osteoarthritis (OA) is a hot topic for drug discovery. Clusterin (CLU) is a glycoprotein involved in inflammation, proliferation, cell death, neoplastic disease, Alzheimer disease and aging. The present study focuses on th...
Autores principales: | Pucci, S., Greggi, C., Polidoro, C., Piro, M. C., Celi, M., Feola, M., Gasbarra, E., Iundusi, R., Mastrangeli, F., Novelli, G., Orlandi, A., Tarantino, U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457035/ https://www.ncbi.nlm.nih.gov/pubmed/30967152 http://dx.doi.org/10.1186/s12967-019-1868-5 |
Ejemplares similares
-
Ascorbic acid reduces Ropivacaine-induced myotoxicity in cultured human osteoporotic skeletal muscle cells
por: Scioli, Maria Giovanna, et al.
Publicado: (2023) -
Hip replacement in femoral neck fractures: the role of cementation and its technical difficulties
por: Gasbarra, Elena, et al.
Publicado: (2022) -
Bone Morphogenetic Proteins and myostatin pathways: key mediator of human sarcopenia
por: Scimeca, Manuel, et al.
Publicado: (2017) -
Hip Osteoarthritis and Osteoporosis: Clinical and Histomorphometric Considerations
por: Tarantino, Umberto, et al.
Publicado: (2014) -
Plasma heavy metal levels correlate with deregulated gene expression of detoxifying enzymes in osteoporotic patients
por: Visconti, V. V., et al.
Publicado: (2023)